Qualitas Enters Distribution Agreement With Lipa Pharmaceuticals

IMPERIAL, Texas—Qualitas Health finalized an exclusive distribution agreement with Lipa Pharmaceuticals for its Almega PL omega-3 ingredient for sale to the dietary supplement industry in Australia and New Zealand.  

Lipa Pharmaceuticals is an Australian contract manufacturer of dietary supplements and OTC pharmaceutical products with core manufacturing competencies, including tablets, soft gelatin capsules, two piece hard gelatin capsules, powders, liquids and creams. Lipa Pharmaceuticals will be responsible for obtaining the appropriate regulatory approvals from the Australian Therapeutic Goods Administration (TGA), providing logistic and sales support, and offering dose-form solutions.  

Almega PL, manufactured by Qualitas Health, is a vegetarian, EPA-rich, polar lipid-structured omega-3 oil. Sourced from Nannochloropsis oculata, a non-GMO strain of microalgae selected for its high level of EPA omega-3 and unique polar-lipid structure, Almega PL contains omega-3 fatty acids with phospholipids and glycolipids that provide superior absorption and digestibility. Farmed microalgae are a source of omega-3s that do not deplete the fragile marine ecosystem. Almega PL is sustainably produced using natural sunlight, non-arable land and low-energy processes. 

 Earlier this year, Qualitas Health finalized a distribution agreement with Xsto Solutions for its Almega PL omega-3 ingredient for sale to the dietary supplement industry in the United States.